Related Experiment Video

Updated: Jul 3, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Progress in the evaluation of CDK inhibitors as anti-tumor agents

Campbell McInnes1

  • 1Pharmaceutical and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC 29208, USA. mcinnes@sccp.sc.edu

Drug Discovery Today
|July 22, 2008
PubMed

Insights

Targeting cyclin-dependent kinases (CDKs) offers therapeutic potential for cancer. However, developing selective CDK inhibitors faces challenges due to multiple CDK roles, hindering drug approval despite ongoing research.

Area of Science:

  • Molecular Biology
  • Pharmacology
  • Oncology

Background:

  • Advances in understanding cell growth and division have led to targeted therapies.
  • Cyclin-dependent kinases (CDKs) are key regulators of the cell cycle and transcriptional processes.
  • CDKs are a significant focus for developing novel pharmacological agents.

Purpose of the Study:

  • To review the complexities and challenges in developing selective CDK inhibitors.
  • To discuss the current status of preclinical and clinical CDK inhibitor evaluations.
  • To analyze issues related to CDK inhibition based on genetic studies and anti-tumor efficacy.

Main Methods:

  • Review of existing scientific literature on CDK inhibitors.
  • Analysis of genetic studies related to CDK functions.
  • Evaluation of preclinical and clinical data for anti-tumor efficacy of CDK inhibitors.

Main Results:

  • Development of pharmacological agents targeting CDKs has progressed significantly.
  • Numerous CDK inhibitors are under investigation, but none have reached drug approval yet.
  • Complexities arise from multiple CDK variants and difficulties in achieving inhibitor selectivity.

Conclusions:

  • The development of selective CDK inhibitors remains a complex challenge in drug discovery.
  • Further research is needed to overcome hurdles in CDK-targeted therapy.
  • Understanding genetic roles and anti-tumor efficacy is crucial for advancing CDK inhibitors.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...